Senior Director, Patient Safety Sciences

Olema Oncology · San Francisco, California · Posted 4d ago

Olema Oncology is a cancer medicines company dedicated to impacting breast cancer and beyond. Our lead program, palazestrant (OP-1250), is a differentiated oral medicine known as a complete estrogen receptor antagonist (CERAN) initially in development for metastatic breast cancer. Our pipeline also

Apply on Olema Oncology's site